Heart failure with preserved
ejection fraction (HFpEF) represents a significant unmet medical need. The
EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on
cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the
hotline session of the 2021 ESC Virtual Congress, the main results of the
EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal
investigator of the study, and heart failure specialist at Charité Berlin,
Germany.
